A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC)-Reference-Cited by-同舟云学术

A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC)

Published:2016-03 Issue:2 Volume:17 Page:119-127
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Zhou Caicun,Huang Yunchao,Wang Donglin,An Changshan,Zhou Fuxiang,Li Yali,Chen Gongyan,Wu Changping,He Jianxing,Wu Gang,Song Xia,Gao Jianfei,Liu Wei,Li Baolan,Shi Jianhua,Huang Cheng,Yu Jingrui,Feng Jueping,Yue Hongmei,Shi Meiqi,Xia Jielai

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group;Fossella;J Clin Oncol,2003

3. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

4. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update;Smith;J Clin Oncol,2015

5. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia;Bodey;Ann Intern Med,1966

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mecapegfilgrastim for prophylaxis of febrile neutropenia in children and adolescents with rhabdomyosarcoma or Ewing sarcoma: a prospective, single-arm, pilot study;BMC Cancer;2024-08-15

2. Mecapegfilgrastim for the prophylaxis of chemotherapy‐induced neutropenia in locally advanced nasopharyngeal carcinoma: A prospective phase II clinical study;Head & Neck;2024-08-11

3. Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer;Int. Journal of Clinical Pharmacology and Therapeutics;2024-03-01

4. An Open-Label, Randomized Phase III Study of Telpegfilgrastim in Preventing Chemotherapy-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer;2024

5. New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy;Frontiers in Oncology;2023-01-05